Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Adam J. Nelson(Clinical Research Institute), Christopher B. Granger(Clinical Research Institute), Tanya Gaynor(Boehringer Ingelheim (United States)), Vanita R. Aroda(Brigham and Women's Hospital), Melissa Magwire(Saint Luke's Health System), Jennifer B. Green, Rodica Pop‐Busui(University of Michigan), Jonathan Pak(Boehringer Ingelheim (United States)), Lisa A. Kaltenbach(Duke University), Çağrı Şenyücel(Eli Lilly (United States)), Caroline R. Richardson(Brown University), Michelle D. Kelsey(Duke University), Julienne K. Kirk(Wake Forest University), Renato D. Lópes(Duke University), Hussein R. Al‐Khalidi(Clinical Research Institute), Darren K. McGuire(Parkland Health & Hospital System), Matthew A. Cavender, Emily C. O’Brien(Duke University), Ildiko Lingvay(Southwestern Medical Center), Neha J. Pagidipati(Duke University), Caryn G. Morse(Wake Forest University)
Cited by 73
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k